1.
Am J Drug Alcohol Abuse
; 34(4): 441-7, 2008.
Article
in English
| MEDLINE
| ID: mdl-18584574
ABSTRACT
The aim of this open-label pilot study was to assess the efficacy and safety of the novel anticonvulsant agent, levetiracetam, for the treatment of alcohol dependence. A maximal dose of 2000 mg was administered daily for 10 weeks to alcohol dependent subjects (n = 20). Mean reported ethanol intake declined significantly from 5.3 to 1.7 standard drinks per day. Levetiracetam was well tolerated by most subjects.